Vivos Therapeutics appoints Gregg C. E. Johnson as independent director

Vivos Therapeutics, Inc.

Gregg C. E. Johnson appointed independent director effective Feb 4, 2026; will serve on Compensation Committee.
Annual cash fee of $48,000 plus $5,000 per committee membership; eligible for stock options under 2024 Equity Incentive Plan.
Johnson previously served as Secretary (2016-2020) and director (2016-2018) of Vivos; has law degree and experience in emerging companies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.